EN PL
CASE REPORT
Relapsing granulomatosis with polyangiitis with severe lung and upper respiratory tract involvement successfully treated with rituximab
 
More details
Hide details
 
Submission date: 2017-06-13
 
 
Final revision date: 2017-07-13
 
 
Acceptance date: 2017-08-14
 
 
Online publication date: 2017-08-31
 
 
Publication date: 2017-08-31
 
 
Reumatologia 2017;55(4):208-212
 
KEYWORDS
TOPICS
ABSTRACT
Granulomatosis with polyangiitis (GPA) is a chronic, relapsing, primary systemic small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies. The disease is characterised by the involvement of various organs. The relapse rate rises from about 20% at 12 months to about 60% at 5 years. The combination of glucocorticoids and cyclophosphamide remains the standard therapy for patients with generalised GPA; nevertheless, some patients do not respond satisfactorily to this treatment. According to EULAR-EDTA recommendations for the management of ANCA-associated vasculitis, RTX should be considered for remission-induction of new-onset as well as major relapse of organ-threatening or life-threatening GPA. Here we present a 35-year-old patient with relapsing GPA successfully treated with RTX. We also highlight the infectious complications of immunosuppressive treatment.
 
REFERENCES (19)
1.
Jennette JC. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis. Clin Exp Immunol 2011; 164 (Suppl 1): 7-10.
 
2.
Mukhtyar C, Luqmani R. Diseasespecific quality indicators, guidelines, and outcome measures in vasculitis. Clin Exp Rheumatol 2007; 25 (6 Suppl 47): 120-129.
 
3.
Bligny D, Mahr A, Toumelin P, et al. Predicting mortality in systemic Wegener’s granulomatosis; a survival analysis based on 93 patients. Arthritis Rheum 2004; 51: 83-91.
 
4.
Yates M, Watts RA, Bajemna IM, et al. EULAR-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 10: 1-12.
 
5.
Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571-2576.
 
6.
Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-123.
 
7.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
 
8.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220.
 
9.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-1780.
 
10.
Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for Refractory Wegener’s Granulomatosis Report of a Prospective, Open-Label Pilot Trial. Am J Respir Crit Care Med 2006; 173; 180-187.
 
11.
Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770-3778.
 
12.
Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-2023.
 
13.
Sznajd J, Mukhtyar C. How to treat ANCAassociated vasculitis: practical messages from 2016 EULAR/ERAEDTA recommendations. Pol Arch Med Wewn 2016; 126: 781- 788.
 
14.
Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75.
 
15.
Heusele M, Clerson P, Guery B, et al. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 2014; 33: 799-805.
 
16.
Trivin C, Tran A, Moulin B, et al. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kid J 2017; 10: 461-469.
 
17.
Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW. Staphylococcus aureus and Wegener’s granulomatosis. Arthritis Res 2002; 4: 77-79.
 
18.
Besada E, Koldingsnes W, Nossent JC. Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis. Peer J 2015; 3: e1051.
 
19.
Varley CD, Deodhar AA, Ehst BD, et al. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-inhibitor therapy. Rheumatology (Oxford) 2014; 53: 332-337.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top